Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
127B INR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.2B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.8B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Onesource Specialty Pharma Ltd
Glance View
Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Onesource Specialty Pharma Ltd is 71%, which is below its 3-year median of 71.2%.
Over the last 10 months, Onesource Specialty Pharma Ltd’s Gross Margin has increased from 67.4% to 71%. During this period, it reached a low of 67.4% on Mar 3, 2025 and a high of 73.8% on Jun 30, 2025.
